FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,642 | +87.0% | 345 | +124.0% | 0.00% | – |
| Q1 2023 | $878 | -81.7% | 154 | -67.6% | 0.00% | – |
| Q4 2022 | $4,793 | -4.1% | 475 | +93.9% | 0.00% | – |
| Q3 2022 | $5,000 | 0.0% | 245 | +31.7% | 0.00% | – |
| Q2 2022 | $5,000 | +25.0% | 186 | +91.8% | 0.00% | – |
| Q1 2022 | $4,000 | -42.9% | 97 | -20.5% | 0.00% | – |
| Q4 2021 | $7,000 | +600.0% | 122 | +408.3% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 24 | +50.0% | 0.00% | – |
| Q2 2021 | $1,000 | -66.7% | 16 | -50.0% | 0.00% | – |
| Q1 2021 | $3,000 | +200.0% | 32 | +166.7% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 12 | -84.2% | 0.00% | – |
| Q3 2019 | $1,000 | -50.0% | 76 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | -96.8% | 76 | -99.7% | 0.00% | -100.0% |
| Q4 2016 | $63,000 | – | 25,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |